Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

Company Overview - Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients with rare and difficult-to-treat diseases [4]. - The company's flagship product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients aged 6 and older [6]. - In January 2023, Catalyst acquired the U.S. commercial rights to FYCOMPA® (perampanel), a medication for epilepsy [6]. - Catalyst also acquired an exclusive license for AGAMREE® (vamorolone), a treatment for Duchenne Muscular Dystrophy, which received FDA approval for commercialization in the U.S. on October 26, 2023 [6]. Financial Results Announcement - Catalyst Pharmaceuticals will release its second quarter 2024 financial results after the market close on August 7, 2024 [4]. - A conference call and webcast to discuss the financial results and provide a business update will be held on August 8, 2024, at 8:30 AM ET [1][5]. Accessibility of Information - The webcast will be accessible under the Investors section on the company's website, and a replay will be available for at least 30 days following the event [5].